21 Dec 2017 07:00
For immediate release 7.00am: 21 December 2017
HVIVO PLC
("hVIVO" or the "Company")
Award of Share Options
hVIVO plc (AIM: HVO), a specialty biopharma company with discovery and clinical testing capabilities, announces that on 20 December 2017 it awarded the following options over ordinary shares of 5.0p each in the Company to Dr Trevor Phillips:
Name | Position | Number of Share Options Awarded | Exercise price per Share | Date of Vesting | Percentage of issued ordinary share capital |
Dr Trevor Phillips | Executive Chairman | 850,000 | 5.0p | 13 November 2020 | 1.09% |
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail:
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1 | Details of the persons discharging managerial responsibilities/persons closely associated | |||||||
a) | Name | Dr Trevor Phillips | ||||||
2 | Reason for the notification | |||||||
a) | Position/ status | Executive Chairman | ||||||
b) | Initial notification/ Amendment | Initial Notification | ||||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||
a) | Name | hVIVO plc | ||||||
b) | Legal Entity Identifier | N/A | ||||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||
a) | Description of the financial instrument, type of instrument Identification code | Options over Ordinary Shares of 5 pence each
ISIN: GB00B6ZM0X53 | ||||||
b) | Nature of the transaction | Award of options over ordinary shares in the Company | ||||||
c) | Currency | GBP | ||||||
d) | Price(s) and volume(s) |
| ||||||
e) | Aggregated information - Aggregated volume - Exercise price
|
850,000 options over ordinary shares 5.0p
| ||||||
f) | Date of the transaction | 20 December 2017 | ||||||
g) | Place of the transaction | London Stock Exchange, AIM | ||||||
For further information please contact:
hVIVO plc | +44 207 756 1300 |
Kym Denny (Chief Executive Officer) | |
Graham Yeatman (Chief Financial & Business Officer) | |
Media Enquiries | +1 919 710 9658 |
Susan Flood (Head of Marketing) | |
Numis Securities Limited | +44 207 260 1000 |
Michael Meade / Freddie Barnfield (Nominated Adviser) | |
James Black / Michael Burke (Corporate Broking) | |
FTI Consulting | |
Simon Conway / Victoria Foster Mitchell (UK) | +44 203 727 1000 |
John Capodanno / Evan Smith (US) | +1 212 850 5705 |
Notes to Editors:
hVIVO plc ("hVIVO"), a specialty biopharma company with discovery and clinical testing capabilities, is pioneering a human-based analytical platform to accelerate drug discovery and development in respiratory and infectious diseases. Leveraging human disease models in flu, RSV and asthma exacerbation, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted more than 50 clinical studies, inoculated over 2500 volunteers and has three first-in-class therapies currently in development with a growing pre-clinical pipeline.
hVIVO (HVO)